Abstract：Estrogen receptor (ER) -α36 is a 36 kD variant of ER-α66, a subtype of ER-α. ER-α36 is mainly expressed in cytoplasm and cell membrane. Compared with ER-α66, it lacks the transcriptional activation domain (AF) -1 and AF-2, and retains the DNA binding domain, partial dimerization domain, and partial distributive binding domain of ER-α66. It can cooperate with various signaling factors such as protein kinase A, protein kinase C and Ca2+, and can rapidly activate non-genomic estrogen signaling pathway in a short period of time to regulate the biological behavior of tumors. Current studies have found that ER-α36 is expressed in human breast cancer, endometrial cancer and other estrogen-related tumor cells. Therefore, the relationship between ER-α36 and malignant tumor is worth studying.
后梦玥 黄照权. 雌激素受体-α36与乳腺癌的关系研究进展[J]. 中国医药导报, 2021, 18(14): 36-38,50.
HOU Mengyue HUANG Zhaoquan. Research progress on the relationship between estrogen receptor-α36 and breast cancer. 中国医药导报, 2021, 18(14): 36-38,50.
[1] Siersb?覸k R，Kumar S，Carroll JS. Signaling pathways and steroid receptors modulating estrogen receptor α function in breast cancer [J]. Genes Dev，2018，32（17/18）：1141-1154.
[2] Mal R，Magner A，David J，et al. Estrogen Receptor Beta（ERβ）：A Ligand Activated Tumor Suppressor [J]. Front Oncol，2020，10：587386.
[3] Feng H，Gusev A，Pasaniuc B，et al. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status [J]. Genet Epidemiol，2020，44（5）：442-468.
[4] Qu LG，Wardan H，Davis ID，et al. Effects of estrogen receptor signaling on prostate cancer carcinogenesis [J]. Transl Res，2020，222：56-66.
[5] Bernardo C，Santos J，Costa C，et al. Estrogen receptors in urogenital schistosomiasis and bladder cancer：Estrogen receptor alpha-mediated cell proliferation [J]. Urol Oncol，2020，38（9）：738e23-738e35.
[6] 中华人民共和国国家卫生健康委员会. 乳腺癌诊疗规范（2018年版）[J].肿瘤综合治疗电子杂志，2019，5（3）：70-99.
[7] Weischenfeldt K，Kirkegaard T，Rasmussen BB，et al. A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis [J]. Acta Oncol，2017，56（9）：1161-1167.
[8] Lykkesfeldt AE，Iversen BR，Jensen MB，et al. Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer [J]. Acta Oncol，2018，57（1）：67-73.
[9] Wang Z，Zhang X，Shen P，et al. A variant of estrogen receptor-{alpha}，hER-{alpha}36： transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling [J]. Proc Natl Acad Sci U S A，2006，103（24）：9063-9068.
[10] Pan X，Zhao B，Song Z，et al. Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells [J]. Pharmacol Sci，2016，130（2）：85-93.
[11] Wang Z，Zhang X，Shen P，et al. Identification，cloning，and expression of human estrogen receptor-alpha36，a novel variant of human estrogen receptor-alpha66 [J]. Biochem Biophys Res Commun，2005，336（4）：1023-1027.
[12] Siegel RL，Miller KD，Jemal A. Cancer statistics，2019 [J]. CA Cancer J Clin，2019，69（1）：7-34.
[13] Ethier JL，Desautels D，Templeton A，et al. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer：a systematic review and meta-analysis [J]. Breast Cancer Res，2017，19（1）：2.
[14] Siegel RL，Miller KD，Jemal A. Cancer statistics，2020 [J]. CA Cancer J Clin，2020，70（1）：7-30.
[15] Li L，Wang Q，Lv X，et al. Expression and localization of estrogen receptor in human breast cancer and its clinical significance [J]. Cell Biochem Biophys，2015，71（1）：63-68.
[16] 晋佳路，朱仁书，马全祥，等.653份乳腺癌组织标本的ER-α36表达结果分析[J].国际检验医学杂志，2015，36（13）：1851-1853.
[17] Xie Y，Hu Y，Zhou N，et al. CAR T-cell therapy for triple-negative breast cancer：Where we are [J]. Cancer Lett，2020，491：121-131.
[18] 李佳艺，游雪叶，叶煌阳，等.三阴乳腺癌原发灶和转移灶中ER-α36、EpCAM、Sox2的表达及临床意义[J].中国老年学杂志，2017，37（17）：4190-4192.
[19] 高建朝，张志生，张淑宇，等.ER-α30和ER-α36在乳腺癌组织的表达及意义[J].临床肿瘤学杂志，2020，25（3）：230-234.
[20] Konan HP，Kassem L，Omarjee S，et al. ERα-36 regulates progesterone receptor activity in breast cancer [J]. Breast Cancer Res，2020，22（1）：50.
[21] Yin L，Wang ZY. Roles of the ER-α36-EGFR/HER2 positive regulatory loops in tamoxifen resistance [J]. Steroids，2016，111：95-99.
[22] 刘君，胥志祥，马晓冬，等.ER-α36在妇科肿瘤中介导非基因组效应研究进展[J].生命科学，2015，27（10）：1299-1305.
[23] Liu Y，Li M，Yu H，et al. lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR-125a-5p [J]. Int J Mol Med，2020，45（2）：497-509.
[24] Li G，Zhang J，Xu Z，et al. ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway [J]. Cancer Manag Res，2020，12：265-275.
[25] Zhong J，Chen YJ，Chen L，et al. PRMT2β，a C-terminal splice variant of PRMT2，inhibits the growth of breast cancer cells [J]. Oncol Rep，2017，38（2）：1303-1311.
[26] Shen Y，Zhong J，Liu J，et al. Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36 [J]. Oncol Rep，2018，39（6）：2604-2612.
[27] Makovec T. Cisplatin and beyond：molecular mechanisms of action and drug resistance development in cancer chemotherapy [J]. Radiol Oncol，2019，53（2）：148-158.
[28] Ghosh S. Cisplatin. The first metal based anticancer drug [J]. Bioorg Chem，2019，88：102925.
[29] Zhu L，Zou J，Zhao Y，et al. ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER2/ERK signaling pathway [J]. J Exp Clin Cancer Res，2018， 37（1）：123.
[30] 金蓓，刘慧，冯江，等.中药在癌症治疗中的应用及其展望[J].智慧健康，2019，5（28）：50-51.
[31] 邹伟，张若琳，孙佳，等.鹿角帽水溶性提取物双相调节乳腺癌细胞增殖[J].辽宁师范大学学报：自然科学版，2019，42（2）：223-228.
[32] Thiebaut C，Chamard-Jovenin C，Chesnel A，et al. Mammary epithelial cell phenotype disruption in vitro and in vivo through ERalpha36 overexpression [J]. PLoS One，2017，12（3）：e0173931.
[33] Velloso FJ，Bianco AF，Farias JO，et al. The crossroads of breast cancer progression：insights into the modulation of major signaling pathways [J]. Onco Targets Ther，2017， 10：5491-5524.
[34] Chamard-Jovenin C，Thiebaut C，Chesnel A，et al. Low-Dose Alkylphenol Exposure Promotes Mammary Epithelium Alterations and Transgenerational Developmental Defects，But Does Not Enhance Tumorigenic Behavior of Breast Cancer Cells [J]. Front Endocrinol（Lausanne），2017，8：272.
京公网安备 11010502046598号